1. Home
  2. PFO vs EQ Comparison

PFO vs EQ Comparison

Compare PFO & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated

PFO

Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated

HOLD

Current Price

$9.04

Market Cap

118.6M

Sector

Finance

ML Signal

HOLD

EQ

Equillium Inc.

HOLD

Current Price

$2.22

Market Cap

129.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PFO
EQ
Founded
1991
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
118.6M
129.0M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
PFO
EQ
Price
$9.04
$2.22
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$8.00
AVG Volume (30 Days)
36.1K
252.6K
Earning Date
01-01-0001
05-25-2026
Dividend Yield
6.51%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$41,095,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.01
$0.29
52 Week High
$9.90
$2.70

Technical Indicators

Market Signals
Indicator
PFO
EQ
Relative Strength Index (RSI) 36.53 53.44
Support Level $8.85 $1.60
Resistance Level $9.84 $2.61
Average True Range (ATR) 0.07 0.24
MACD -0.02 -0.01
Stochastic Oscillator 26.29 52.54

Price Performance

Historical Comparison
PFO
EQ

About PFO Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated

Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.

About EQ Equillium Inc.

Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.

Share on Social Networks: